These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33636388)

  • 21. Mutant VPS35-D620N induces motor dysfunction and impairs DAT-mediated dopamine recycling pathway.
    Huang Y; Huang H; Zhou L; Li J; Chen X; Thomas J; He X; Guo W; Zeng Y; Low BC; Liang F; Zeng J; Ross CA; Tan EK; Smith W; Pei Z
    Hum Mol Genet; 2022 Nov; 31(22):3886-3896. PubMed ID: 35766879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impaired striatal dopamine release in homozygous Vps35 D620N knock-in mice.
    Ishizu N; Yui D; Hebisawa A; Aizawa H; Cui W; Fujita Y; Hashimoto K; Ajioka I; Mizusawa H; Yokota T; Watase K
    Hum Mol Genet; 2016 Oct; 25(20):4507-4517. PubMed ID: 28173004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endosomal dysfunction in iPSC-derived neural cells from Parkinson's disease patients with VPS35 D620N.
    Bono K; Hara-Miyauchi C; Sumi S; Oka H; Iguchi Y; Okano HJ
    Mol Brain; 2020 Oct; 13(1):137. PubMed ID: 33032646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of the VPS35 D620N mutation in Parkinson's disease.
    Mohan M; Mellick GD
    Parkinsonism Relat Disord; 2017 Mar; 36():10-18. PubMed ID: 27964832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Formation of retromer transport carriers is disrupted by the Parkinson disease-linked Vps35 D620N variant.
    Cui Y; Yang Z; Flores-Rodriguez N; Follett J; Ariotti N; Wall AA; Parton RG; Teasdale RD
    Traffic; 2021 Apr; 22(4):123-136. PubMed ID: 33347683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Parkinson's disease related mutant VPS35 (D620N) amplifies the LRRK2 response to endolysosomal stress.
    McCarron KR; Elcocks H; Mortiboys H; Urbé S; Clague MJ
    Biochem J; 2024 Feb; 481(4):265-278. PubMed ID: 38299383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of VPS35 p.D620N mutation-related Parkinson's disease in a Taiwanese family with successful bilateral subthalamic nucleus deep brain stimulation: a case report and literature review.
    Chen YF; Chang YY; Lan MY; Chen PL; Lin CH
    BMC Neurol; 2017 Oct; 17(1):191. PubMed ID: 28985717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. VPS35 mutation in Japanese patients with typical Parkinson's disease.
    Ando M; Funayama M; Li Y; Kashihara K; Murakami Y; Ishizu N; Toyoda C; Noguchi K; Hashimoto T; Nakano N; Sasaki R; Kokubo Y; Kuzuhara S; Ogaki K; Yamashita C; Yoshino H; Hatano T; Tomiyama H; Hattori N
    Mov Disord; 2012 Sep; 27(11):1413-7. PubMed ID: 22991136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VPS35 regulates cell surface recycling and signaling of dopamine receptor D1.
    Wang C; Niu M; Zhou Z; Zheng X; Zhang L; Tian Y; Yu X; Bu G; Xu H; Ma Q; Zhang YW
    Neurobiol Aging; 2016 Oct; 46():22-31. PubMed ID: 27460146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parkin mediates the ubiquitination of VPS35 and modulates retromer-dependent endosomal sorting.
    Williams ET; Glauser L; Tsika E; Jiang H; Islam S; Moore DJ
    Hum Mol Genet; 2018 Sep; 27(18):3189-3205. PubMed ID: 29893854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EIF4G1 R1205H and VPS35 D620N mutations are rare in Parkinson's disease from South Africa.
    Blanckenberg J; Ntsapi C; Carr JA; Bardien S
    Neurobiol Aging; 2014 Feb; 35(2):445.e1-3. PubMed ID: 24080171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced Hyaluronan Signaling and Autophagy Dysfunction by VPS35 D620N.
    Rahman AA; Soto-Avellaneda A; Yong Jin H; Stojkovska I; Lai NK; Albright JE; Webb AR; Oe E; Valarde JP; Oxford AE; Urquhart PE; Wagner B; Brown C; Amado I; Vasquez P; Lehning N; Grozdanov V; Pu X; Danzer KM; Morrison BE
    Neuroscience; 2020 Aug; 441():33-45. PubMed ID: 32540366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parkinson's Disease Causative Mutation in Vps35 Disturbs Tetherin Trafficking to Cell Surfaces and Facilitates Virus Spread.
    Ding Y; Li Y; Chhetri G; Peng X; Wu J; Wang Z; Zhao B; Zhao W; Li X
    Cells; 2021 Mar; 10(4):. PubMed ID: 33800686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding the contributions of VPS35 and the retromer in neurodegenerative disease.
    Williams ET; Chen X; Otero PA; Moore DJ
    Neurobiol Dis; 2022 Aug; 170():105768. PubMed ID: 35588987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of LRRK2 kinase activity rescues deficits in striatal dopamine physiology in VPS35 p.D620N knock-in mice.
    Bu M; Follett J; Deng I; Tatarnikov I; Wall S; Guenther D; Maczis M; Wimsatt G; Milnerwood A; Moehle MS; Khoshbouei H; Farrer MJ
    NPJ Parkinsons Dis; 2023 Dec; 9(1):167. PubMed ID: 38110354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parkinson's disease-associated VPS35 mutant reduces mitochondrial membrane potential and impairs PINK1/Parkin-mediated mitophagy.
    Ma KY; Fokkens MR; Reggiori F; Mari M; Verbeek DS
    Transl Neurodegener; 2021 Jun; 10(1):19. PubMed ID: 34127073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. D620N mutation in the VPS35 gene and R1205H mutation in the EIF4G1 gene are uncommon in the Greek population.
    Kalinderi K; Bostantjopoulou S; Katsarou Z; Dimikiotou M; Fidani L
    Neurosci Lett; 2015 Oct; 606():113-6. PubMed ID: 26300542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical manifestations of Parkinson's disease harboring VPS35 retromer complex component p.D620N with long-term follow-up.
    Ishiguro M; Li Y; Yoshino H; Daida K; Ishiguro Y; Oyama G; Saiki S; Funayama M; Hattori N; Nishioka K
    Parkinsonism Relat Disord; 2021 Mar; 84():139-143. PubMed ID: 33611076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vacuolar protein sorting 35 (Vps35) rescues locomotor deficits and shortened lifespan in Drosophila expressing a Parkinson's disease mutant of Leucine-Rich Repeat Kinase 2 (LRRK2).
    Linhart R; Wong SA; Cao J; Tran M; Huynh A; Ardrey C; Park JM; Hsu C; Taha S; Peterson R; Shea S; Kurian J; Venderova K
    Mol Neurodegener; 2014 Jun; 9():23. PubMed ID: 24915984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contributions of VPS35 Mutations to Parkinson's Disease.
    Rahman AA; Morrison BE
    Neuroscience; 2019 Mar; 401():1-10. PubMed ID: 30660673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.